A review of the effectiveness of vaccine potency control testing

International Journal for Parasitology

Volumn 33, Issue 5-6, 2003, Pages 507-516

  McVey, David Scott ^a   Galvin, Jeffrey E ^a   Olson, Steven C ^b  

^a ZOETIS   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Efficacy; Potency; Potency tests; Review; Vaccine

Indexed keywords

ALUMINUM DERIVATIVE; BACTERIN; BRUCELLA VACCINE; CHICKENPOX VACCINE; CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LEPTOSPIROSIS VACCINE; LIVE VACCINE; MEASLES VACCINE; RABIES VACCINE; TETANUS TOXOID; TOXOID; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

VACCINATION;

ANTIGEN PRESENTATION; BACTERIAL VIRULENCE; BATCH PROCESS; BOVINE DIARRHEA VIRUS; BRUCELLA ABORTUS; BRUCELLOSIS; CATTLE DISEASE; CHICKENPOX; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIPHTHERIA; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG QUALITY; DRUG SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; LEPTOSPIRA; LEPTOSPIROSIS; MEASLES; METHODOLOGY; NONHUMAN; PERTUSSIS; PREDICTION; PROCESS CONTROL; RABIES; REVIEW; SHELF LIFE; TETANUS; TREATMENT FAILURE; VACCINE PRODUCTION; VACCINIA; VALIDATION PROCESS;

EID: 0037686479     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(03)00067-5     Document Type: Review

References (77)

1. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science. 272:1996;54-60.
2. Anders J.F., Jacobson R.M., Poland G.A., Jacobsen S.J., Wollan P.C. Secondary failure rates of measles vaccines: a metaanalysis of published studies. The Pediatric Infectious Disease Journal. 15:1996;62-66.
3. Bajenoff M., Wurtz O., Guerder S. Repeated antigen exposure is necessary for the differentiation, but not initial proliferation, of naive CD4(+) T cells. Journal of Immunology. 168:2002;1723-1729.
4. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
5. Baxter A.G. Louis Pasteur's beer of revenge. Nature Reviews Immunology. 1:2001;229-232.
6. Beer M., Hehnen H.R., Wolfmeyer A., Poll G., Kaaden O.R., Wolf G. A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I. Veterinary Microbiology. 77:2000;195-208.
7. Bolin C.A., Alt D.P. Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar hardjo. American Journal of Veterinary Research. 62:2001;995-1000.
8. Breukels M.A., Spanjaard L., Sanders L.A., Rijkers G.T. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants. Clinical Infectious Diseases. 32:2001;1700-1705.
9. Burke C.J., Hsu T.A., Volkin D.B. Formulation, stability, and delivery of live attenuated vaccines for human use. Critical Reviews in Therapeutic Drug Carrier Systems. 16:1999;1-83.
10. Busch D.H., Pamer E.G. T-cell affinity maturation by selective expansion during infection. The Journal of Experimental Medicine. 189:1999;701-710.
11. + T cells during an acute virus infection. Immunity. 8:1998;167-175.
12. Buxton Bridges C., Fukuda K., Holman R.C., De Guzman A.M., Hodder R.A., Gomolin I.H., Galligan G.K., Leib H.B., Gallo R.J., Regnery H.L., Arden N.H., Cox N.J. Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. Vaccine. 18:2000;1103-1109.
13. Dean H.J., Leyh R. Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine. 17:1999;1117-1124.
14. Deming M.S., Linkins R.W., Jaiteh K.O., Hull H.F. The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. The Journal of Infectious Diseases. 175:1997;S254-S257.
15. Dietz V., Milstien J.B., van Loon F., Cochi S., Bennett J. Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Bulletin of the World Health Organization. 74:1996;619-628.
16. Dutta S.K., Vemulapalli R., Biswas B. Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses. Journal of Clinical Microbiology. 36:1998;506-512.
17. Fehr D., Holznagel E., Bolla S., Hauser B., Herrewegh A.A., Horzinek M.C., Lutz H. Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine. 15:1997;1101-1109.
18. Fleming D.M., Zambon M. Update on influenza and other viral pneumonias. Current Opinion in Infectious Diseases. 14:2001;199-204.
19. Frey S.E., Newman F.K., Cruz J., Shelton W.B., Tennant J.M., Polach T., Rothman A.L., Kennedy J.S., Wolff M., Belshe R.B., Ennis F.A. Dose-related effects of smallpox vaccine. The New England Journal of Medicine. 346:2002;1275-1280.
20. Fulton R.W., Burge L.J. Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine. 19:2000;264-274.
21. Gandon S., Mackinnon M.J., Nee S., Read A.F. Imperfect vaccines and the evolution of pathogen virulence. Nature. 414:2001;751-756.
22. Garland A.J. Vital elements for the successful control of foot-and-mouth disease by vaccination. Vaccine. 17:1999;1760-1766.
23. Garpenholt O., Hugosson S., Fredlund H., Giesecke J., Olcen P. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatrica. 89:2000;471-474.
24. Gonzalez-Stawinski G.V., Yu P.B., Love S.D., Parker W., Davis R.D. Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clinical Immunology. 98:2001;175-179.
25. Hamers C., di Valentin E., Lecomte C., Lambot M., Joris E., Genicot B., Pastoret P.P. Virus neutralizing antibodies against a panel of 18 BVDV isolates in calves vaccinated with Rispoval RS-BVD. Journal of Veterinary Medicine Series B. 47:2000;721-726.
26. Hamers C., di Valentin E., Lecomte C., Lambot M., Joris E., Genicot B., Pastoret P.P. Virus neutralising antibodies against 22 bovine viral diarrhoea virus isolates in vaccinated calves. Veterinary Journal. 163:2002;61-67.
27. He C., Nomura F., Itoga S., Isobe K., Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. Journal of Gastroenterology and Hepatology. 16:2001;1373-1377.
28. Heath P.T., Booy R., Azzopardi H.J., Slack M.P., Bowen-Morris J., Griffiths H., Ramsay M.E., Deeks J.J., Moxon E.R. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. The Journal of the American Medical Association. 284:2000;2334-2340.
29. Heath P.T., McVernon J. The UK Hib vaccine experience. Archives of Disease in Childhood. 86:2002;396-399.
30. Heine H.G., Foord A.J., Young P.L., Hooper P.T., Lehrbach P.R., Boyle D.B. Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens. Virus Research. 50:1997;23-33.
31. Hohdatsu T., Sato K., Tajima T., Koyama H. Neutralizing feature of commercially available feline calicivirus (FCV) vaccine immune sera against FCV field isolates. The Journal of Veterinary Medical Science. 61:1999;299-301.
32. Hougs L., Juul L., Ditzel H.J., Heilmann C., Svejgaard A., Barington T. The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. Journal of Immunology. 162:1999;224-237.
33. Iezzi G., Scotet E., Scheidegger D., Lanzavecchia A. The interplay between the duration of TCR and cytokine signalling determines T-cell polarization. European Journal of Immunology. 29:1999;4092-4101.
34. Jackson L.A., Falls S., Yu O., George J., Pietrobon P.J., Rubanowice D., Froeschle J. Diphtheria antitoxin levels among children primed with a diphtheria and tetanus toxoids and acellular pertussis vaccine lot with a subpotent diphtheria toxoid component. The Journal of Infectious Diseases. 183:2001;1698-1700.
35. + T-cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunology. 2:2001;415-422.
36. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Reviews Immunology. 2:2002;251-262.
37. + T cells by primary HIV-1 infection: potential mechanism of vaccine failure. Journal of Immunology. 158:1997;807-815.
38. Kenyon T.A., Izurieta H., Shulman S.T., Rosenfeld E., Miller M., Daum R., Strebel P.M. Large outbreak of pertussis among young children in Chicago, 1993: investigation of potential contributing factors and estimation of vaccine effectiveness. The Pediatric Infectious Disease Journal. 15:1996;655-661.
39. Levings R.L., Henderson L.M., Metz C.A. In vitro potency assays for nonreplicating veterinary vaccines: comparison to in vivo assays and considerations in assay development. Veterinary Microbiology. 37:1993;201-219.
40. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proceedings of the National Academy of Sciences of the United States of America. 96:1997;6571-6576.
41. Lu Y.F., Singh M., Cerny J. Canonical germinal center B cells may not dominate the memory response to antigenic challenge. International Immunology. 13:2001;643-655.
42. Mahon B.P., Brady M.T., Mills K.H. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. The Journal of Infectious Diseases. 181:2000;2087-2091.
43. Manz R.A., Lohning M., Cassese G., Thiel A., Radbruch A. Survival of long-lived plasma cells is independent of antigen. International Immunology. 10:1998;1703-1711.
44. Naiman B.M., Alt D., Bolin C.A., Zuerner R., Baldwin C.L. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and γδ T lymphocytes. Infection and Immunity. 69:2001;7550-7558.
45. Narita M., Matsuzono Y., Takekoshi Y., Yamada S., Itakura O., Kubota M., Kikuta H., Togashi T. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clinical and Diagnostic Laboratory Immunology. 5:1998;799-803.
46. Narita M., Yamada S., Matsuzono Y., Itakura O., Togashi T., Kikuta H. Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Clinical and Diagnostic Laboratory Immunology. 3:1996;211-215.
47. Ochsenbein A.F., Pinschewer D.D., Sierro S., Horvath E., Hengartner H., Zinkernagel R.M. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;13263-13268.
48. Olsen S.C. Responses of adult cattle to vaccination with a reduced dose of Brucella abortus strain RB51. Research in Veterinary Science. 69:2000;135-140.
49. Omilabu S.A., Oyefolu A.O., Ojo O.O., Audu R.A. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria. African Journal of Medicine and Medical Sciences. 28:1999;209-212.
50. Parr M.B., Parr E.L. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology. 101:2000;126-131.
51. Pasteur L. De l'attenuation des virus. Quarterly Congress International Hygeine Demographic. 1:1882;145.
52. April 8 Pasteur L. Remarks on anthracic vaccination as a prophylactic od splenic fever. British Medical Journal. 1882;489.
53. Paton D.J., Lowings J.P., Barrett A.D. Epitope mapping of the gp53 envelope protein of bovine viral diarrhea virus. Virology. 190:1992;763-772.
54. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., Heinonen O.P. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccines. American Journal of Epidemiology. 148:1998;1103-1110.
55. Pedersen N.C., Elliott J.B., Glasgow A., Poland A., Keel K. An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. Veterinary Microbiology. 73:2000;281-300.
56. Pedersen N.C., Hawkins K.F. Mechanisms for persistence of acute and chronic feline calicivirus infections in the face of vaccination. Veterinary Microbiology. 47:1995;141-156.
57. Radford A.D., Dawson S., Wharmby C., Ryvar R., Gaskell R.M. Comparison of serological and sequence-based methods for typing feline calcivirus isolates from vaccine failures. The Veterinary Record. 146:2000;117-123.
58. Radford A.D., Sommerville L., Ryvar R., Cox M.B., Johnson D.R., Dawson S., Gaskell R.M. Endemic infection of a cat colony with a feline calicivirus closely related to an isolate used in live attenuated vaccines. Vaccine. 19:2001;4358-4362.
59. Radford A.D., Sommerville L.M., Dawson S., Kerins A.M., Ryvar R., Gaskell R.M. Molecular analysis of isolates of feline calicivirus from a population of cats in a rescue shelter. The Veterinary Record. 149:2001;477-481.
60. Reed N.E., Varney W.C., Goddard R.D., Wyeth P.J. The maintenance of challenge strains used in the potency test for canine leptospira vaccines. Biologicals. 28:2000;25-28.
61. Rooijakkers E.J., Nieuwenhuijs J.H., Vermeulen A.A., van Steenis G., Osterhaus A.D. Potency of veterinary rabies vaccines in The Netherlands: a case for continued vigilance. The Veterinary Quarterly. 18:1996;146-150.
62. Rooijakkers E.J., Uittenbogaard J.P., Groen J., Osterhaus A.D. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. Journal of Virological Methods. 58:1996;111-119.
63. Savage P.A., Boniface J.J., Davis M.M. A kinetic basis for T-cell repertoire selection during an immune response. Immunity. 10:1999;485-492.
64. Shams H., Heron I. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model. APMIS. 106:1998;526-534.
65. Shimoda M., Nakamura T., Takahashi Y., Asanuma H., Tamura S., Kurata T., Mizuochi T., Azuma N., Kanno C., Takemori T. Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue. The Journal of Experimental Medicine. 194:2001;1597-1607.
66. Sin J.I., Kim J.J., Boyer J.D., Ciccarelli R.B., Higgins T.J., Weiner D.B. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. Journal of Virology. 73:1999;501-509.
67. Stevens M.G., Hennager S.G., Olsen S.C., Cheville N.F. Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with Brucella abortus 19 or RB51. Journal of Clinical Microbiology. 32:1994;1065-1066.
68. Stevens M.G., Olsen S.C., Cheville N.F. Comparative analysis of immune responses in cattle vaccinated with Brucella abortus strain 19 or strain RB51. Veterinary Immunology and Immunopathology. 44:1995;223-235.
69. Strady C., Jaussaud R., Beguinot I., Lienard M., Strady A. Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine. 18:2000;2661-2667.
70. Van Campen H., Vorpahl P., Huzurbazar S., Edwards J., Cavender J. A case report: evidence for type 2 bovine viral diarrhea virus (BVDV)-associated disease in beef herds vaccinated with a modified-live type 1 BVDV vaccine. Journal of Veterinary Diagnostic Investigation. 12:2000;263-265.
71. van Stipdonk M.J., Lemmens E.E., Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nature Immunology. 2:2001;423-429.
72. Weeks M.L., Gallagher A., Romero C.H. Sequence analysis of feline caliciviruses isolated from the oral cavity of clinically normal domestic cats (Felis catus) in Florida. Research in Veterinary Science. 71:2001;223-225.
73. + T cells in intracellular bacterial infections of mice. Research in Immunology. 147:1996;519-524.
74. Wormser G.P., Nowakowski J., Nadelman R.B., Schwartz I., McKenna D., Holmgren D., Aguero-Rosenfeld M. Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State. Infection. 26:1998;208-212.
75. Youwang Y., Ping W., Feng C. Serological and epidemiological effects and influence factors of primary immunization with current live attenuated measles vaccine (Hu191) among infants aged 6-15 months. Vaccine. 19:2001;1998-2005.
76. Zubler R.H. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Seminars in Immunopathology. 23:2001;405-419.
77. Zuckerman A.J. Effects of hepatitis B virus mutants on efficacy of vaccination. Lancet. 356:2000;1382-1384.